DK0667341T3 - 4-Amino-1-piperidylbenzoylguanidiner som Na+/H+-antiporter-inhibitorer - Google Patents

4-Amino-1-piperidylbenzoylguanidiner som Na+/H+-antiporter-inhibitorer

Info

Publication number
DK0667341T3
DK0667341T3 DK95101575T DK95101575T DK0667341T3 DK 0667341 T3 DK0667341 T3 DK 0667341T3 DK 95101575 T DK95101575 T DK 95101575T DK 95101575 T DK95101575 T DK 95101575T DK 0667341 T3 DK0667341 T3 DK 0667341T3
Authority
DK
Denmark
Prior art keywords
amino
alk
hal
opt
alkylene
Prior art date
Application number
DK95101575T
Other languages
English (en)
Inventor
Norbert Dr Beier
Ingeborg Dr Lues
Klaus-Otto Dr Minck
Rolf Dr Gericke
Manfred Dr Baumgarth
Dieter Dr Dorsch
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK0667341T3 publication Critical patent/DK0667341T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DK95101575T 1994-02-10 1995-02-07 4-Amino-1-piperidylbenzoylguanidiner som Na+/H+-antiporter-inhibitorer DK0667341T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4404183A DE4404183A1 (de) 1994-02-10 1994-02-10 4-Amino-1-piperidylbenzoylguanidine

Publications (1)

Publication Number Publication Date
DK0667341T3 true DK0667341T3 (da) 2001-10-22

Family

ID=6509922

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95101575T DK0667341T3 (da) 1994-02-10 1995-02-07 4-Amino-1-piperidylbenzoylguanidiner som Na+/H+-antiporter-inhibitorer

Country Status (22)

Country Link
US (1) US5461066A (da)
EP (1) EP0667341B1 (da)
JP (1) JPH07267926A (da)
KR (1) KR950321212A (da)
CN (1) CN1082948C (da)
AT (1) ATE204864T1 (da)
AU (1) AU693496B2 (da)
CA (1) CA2142070A1 (da)
CZ (1) CZ286681B6 (da)
DE (2) DE4404183A1 (da)
DK (1) DK0667341T3 (da)
ES (1) ES2161789T3 (da)
GR (1) GR3036839T3 (da)
HU (1) HU215601B (da)
NO (1) NO303685B1 (da)
PL (1) PL179255B1 (da)
PT (1) PT667341E (da)
RU (1) RU2140412C1 (da)
SK (1) SK281721B6 (da)
TW (1) TW291476B (da)
UA (1) UA43834C2 (da)
ZA (1) ZA951059B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4328352A1 (de) * 1993-08-24 1995-03-02 Hoechst Ag Substituierte N,N'-Di-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4421495A1 (de) * 1994-06-20 1995-12-21 Merck Patent Gmbh Heterocyclyloxy-benzoylguanidine
DE4430212A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
DE4430861A1 (de) * 1994-08-31 1996-03-07 Merck Patent Gmbh Heterocyclyl-benzoylguanidine
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
DE19608161A1 (de) * 1996-03-04 1997-09-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19608162A1 (de) * 1996-03-04 1997-09-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19859727A1 (de) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
US7620611B1 (en) * 1999-07-20 2009-11-17 Trilithic, Inc. Neural networks for ingress monitoring
EP1263729B1 (en) 2000-03-06 2006-12-20 Acadia Pharmaceuticals Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
EP1355899A1 (en) * 2001-01-31 2003-10-29 Pfizer Products Inc. Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
KR100974901B1 (ko) * 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
KR20050008846A (ko) * 2002-06-24 2005-01-21 아카디아 파마슈티칼스 인코포레이티드 세로토닌 수용체 제제로서의 n-치환된 피페리딘 유도체
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
EP1556045B1 (en) * 2002-10-04 2006-08-02 Ucb, S.A. 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments
CA2512639C (en) 2003-01-16 2012-10-30 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
RU2391340C2 (ru) * 2004-08-11 2010-06-10 Киорин Фармасьютикал Ко., Лтд. Новое циклическое производное аминобензойной кислоты
KR101260036B1 (ko) * 2004-09-27 2013-05-06 아카디아 파마슈티칼스 인코포레이티드 N-(4-플루오로벤질)-n-(1-메틸피페리딘-4-일)-n'-(4-(2-메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ,インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP3325444B1 (en) 2015-07-20 2021-07-07 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
DE4117904A1 (de) * 1991-05-31 1992-12-03 Basf Ag Substituierte n-phenylpiperidine
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
DK0589336T3 (da) * 1992-09-22 1997-06-16 Hoechst Ag Benzylguanidiner, fremgangsmåde til deres fremstilling samt deres anvendelse som antiarytmetika
DE59309360D1 (de) * 1992-12-02 1999-03-18 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
DE59509543D1 (de) 2001-10-04
NO303685B1 (no) 1998-08-17
TW291476B (da) 1996-11-21
GR3036839T3 (en) 2002-01-31
PL307190A1 (en) 1995-08-21
DE4404183A1 (de) 1995-08-17
AU693496B2 (en) 1998-07-02
ZA951059B (en) 1995-10-13
JPH07267926A (ja) 1995-10-17
HUT72306A (en) 1996-04-29
PT667341E (pt) 2001-12-28
AU1157195A (en) 1995-08-17
CZ286681B6 (en) 2000-06-14
SK281721B6 (sk) 2001-07-10
RU95101843A (ru) 1997-03-10
SK15795A3 (en) 1995-09-13
NO950485D0 (no) 1995-02-09
NO950485L (no) 1995-08-11
PL179255B1 (pl) 2000-08-31
ES2161789T3 (es) 2001-12-16
EP0667341A1 (de) 1995-08-16
HU215601B (hu) 1999-01-28
CN1112550A (zh) 1995-11-29
US5461066A (en) 1995-10-24
CN1082948C (zh) 2002-04-17
CZ32795A3 (en) 1995-10-18
RU2140412C1 (ru) 1999-10-27
HU9500396D0 (en) 1995-03-28
EP0667341B1 (de) 2001-08-29
CA2142070A1 (en) 1995-08-11
ATE204864T1 (de) 2001-09-15
UA43834C2 (uk) 2002-01-15
KR950321212A (ko) 1995-12-20

Similar Documents

Publication Publication Date Title
DE59509543D1 (de) 4-Amino-1-piperidylbenzoylguanidine als Na+/H+-antiporter Inhibitoren
AR026351A1 (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii
EP1130016A4 (en) DERIVATIVES OF THIOCARBAMATE ACID
KR960007564A (ko) 헤테로시클릴-벤조일구아니딘 유도체
DE69232681D1 (de) 4-oxozyklische harnstoffe mit antiarrhythmische und entfibrillatorische wirkung
ES2058531T3 (es) Amidas de mercapto-fenilalcanoilaminoacidos, su preparacion y su uso como inhibidores de colagenasa.
DE3876402D1 (de) N-(2-alkyl-3-mercapto-1,5-dioxoalkyl)glycinamid-derivate und deren verwendung als kollagenase-inhibitoren.
MX9306257A (es) Compuestos fotocromicos, su preparacion y su uso.
ATE178063T1 (de) Zyklische harnstoffe mit antiarrhythmischer und antifibrillatorischer wirkung
DK498889D0 (da) Substituerede aromatiske forbindelser med virkning paa centralnervesystemet
DE3679977D1 (de) Pyran-derivate.